|
1
|
Barnard ME, Boeke CE and Tamimi RM:
Established breast cancer risk factors and risk of intrinsic tumor
subtypes. Biochim Biophys Acta. 1856:73–85. 2015.PubMed/NCBI
|
|
2
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lobbezoo DJ, van Kampen RJ, Voogd AC,
Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ,
Peters FP, van Riel JM, Peters NA, et al: Prognosis of metastatic
breast cancer subtypes: The hormone receptor/HER2-positive subtype
is associated with the most favorable outcome. Breast Cancer Res
Treat. 141:507–514. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Scott GK, Robles R, Park JW, Montgomery
PA, Daniel J, Holmes WE, Lee J, Keller GA, Li WL, Fendly BM, et al:
A truncated intracellular HER2/neu receptor produced by alternative
RNA processing affects growth of human carcinoma cells. Mol Cell
Biol. 13:2247–2257. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jackson C, Browell D, Gautrey H and
Tyson-Capper A: Clinical significance of HER-2 splice variants in
breast cancer progression and drug resistance. Int J Cell Biol.
2013:9735842013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Castiglioni F, Tagliabue E, Campiglio M,
Pupa SM, Balsari A and Ménard S: Role of exon-16-deleted HER2 in
breast carcinomas. Endocr Relat Cancer. 13:221–232. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mitra D, Brumlik MJ, Okamgba SU, Zhu Y,
Duplessis TT, Parvani JG, Lesko SM, Brogi E and Jones FE: An
oncogenic isoform of HER2 associated with locally disseminated
breast cancer and trastuzumab resistance. Mol Cancer Ther.
8:2152–2162. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kwong KY and Hung MC: A novel splice
variant of HER2 with increased transformation activity. Mol
Carcinog. 23:62–68. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Siegel PM, Ryan ED, Cardiff RD and Muller
WJ: Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3
are involved in the induction of mammary tumors in transgenic mice:
Implications for human breast cancer. EMBO J. 18:2149–2164. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Alajati A, Sausgruber N, Aceto N, Duss S,
Sarret S, Voshol H, Bonenfant D and Bentires-Alj M: Mammary tumor
formation and metastasis evoked by a HER2 splice variant. Cancer
Res. 73:5320–5327. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Marchini C, Gabrielli F, Iezzi M, Zenobi
S, Montani M, Pietrella L, Kalogris C, Rossini A, Ciravolo V,
Castagnoli L, et al: The human splice variant Δ16HER2 induces rapid
tumor onset in a reporter transgenic mouse. PLoS One. 6:e187272011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Castagnoli L, Iezzi M, Ghedini GC,
Ciravolo V, Marzano G, Lamolinara A, Zappasodi R, Gasparini P,
Campiglio M, Amici A, et al: Activated d16HER2 homodimers and SRC
kinase mediate optimal efficacy for trastuzumab. Cancer Res.
74:6248–6259. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH
and van de Vijver MJ: WHO Classification of tumours of the breast.
IARC; Lyon: 2012
|
|
16
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American society of
clinical oncology/college of American pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Allred DC, Harvey JM, Berardo M and Clark
GM: Prognostic and predictive factors in breast cancer by
immunohistochemical analysis. Mod Pathol. 11:155–168.
1998.PubMed/NCBI
|
|
19
|
Zhang S, Huang WC, Li P, Guo H, Poh SB,
Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z, et al: Combating
trastuzumab resistance by targeting SRC, a common node downstream
of multiple resistance pathways. Nat Med. 17:461–469. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Natori A, Hayashi N, Soejima K, Deshpande
GA, Takahashi O, Cristofanilli M, Ueno NT and Yamauchi H: A
comparison of epidemiology, biology, and prognosis of inflammatory
breast cancer in Japanese and US populations. Clin Breast Cancer.
13:460–464. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bianchini G and Gianni L: The immune
system and response to HER2-targeted treatment in breast cancer.
Lancet Oncol. 15:e58–e68. 2014. View Article : Google Scholar : PubMed/NCBI
|
